Jayasree Iyer – CEO, Access to Medicine Foundation
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Chiesi is an Italian pharmaceutical family company founded in 1935 by Giacomo Chiesi. Since 2007, Chiesi has been active in the Netherlands. Headquartered in Parma, Italy, the company has a presence in 66 countries. Chiesi provides innovative pharmaceutical solutions and medications, and contributes to the improvement of diagnosis and treatment through the Knowledge Chiesi College. In addition, Chiesi promotes scientific research and talent from the Chiesi Foundation. Chiesi is active on five continents and has four research centers and three manufacturing facilities, and employs over 4000 people. The company had 2014 worldwide sales of over 1.4 billion euros and a turnover of 33 million euros.
Chiesi adopts a personal and honest approach in an organization where employees are given the opportunity to develop their entrepreneurial spirit. We are an organization which strives to develop therapies for patients. Chiesi Netherlands comprises two different departments, General Care and Special Care. General Care engages in drug treatments in the field of asthma and COPD. Special Care focuses on cystic fibrosis, respiratory distress syndrome in premature infants (neonatology), hyaline membrane disease, kidney and liver transplants, stem cell therapy and genetic fat metabolism disease LPL deficiency. With 53 employees in the country, Chiesi is a modest but growing force in the Netherlands.
Contact
Chiesi Pharmaceuticals B.V.
Lange Kleiweg 52 J, 2288 GK Rijswijk
Postbus 1147, 2280 CC Rijswijk
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
See our Cookie Privacy Policy Here
